Insight

Sharlene Gill: Duration of adjuvant treatment in Stage III colon cancer

Sharlene Gill/ctg.queensu.ca

Oct 13, 2024, 10:44

Sharlene Gill: Duration of adjuvant treatment in Stage III colon cancer

Sharlene Gill shared a post on X:

“Duration of adjuvant treatment in s3 colon cancer in JCO Oncology Practice.
6 yrs since IDEA & patients with low-risk s3 are still getting 6months of oxaliplatin AT.

-longer duration in younger pts…with neuropathy
-young age is prognostic – let’s avoid the temptation of over treatment.”

Sharlene Gill

Aparna Raj Parikh shared the above post on X, adding:

“One of few who disagree (a bit). IDEA non inferiority & accept some (albeit tiny) efficacy loss. We push oxali too much but ETD data shows 8ish month sweet spot.

Talk about it with everyone but folfox is easy (dislike cape) & low threshold to stop BEFORE persistent neuropathy.”

Three Versus Six Months of Adjuvant Oxaliplatin-Containing Chemotherapy for Patients With Stage III Colorectal Cancer: A Contemporary Real-World Analysis

Authors: Tharani Krishnan, et al.

Sharlene Gill: Duration of adjuvant treatment in Stage III colon cancer

Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver, Canada. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and Chair of the UBC Department of Medicine Mentoring Committee. She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists. Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.

Dr. Aparna R. Parikh is an Associate Professor of Medicine at Harvard Medical School and a Gastrointestinal Oncologist at Massachusetts General Hospital, where she has been practicing since September 2016. She is affiliated with the Tucker Gosnell Center for Gastrointestinal Cancers and the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Parikh’s clinical interests include clinical trials, clinical research, gastrointestinal cancer, global health, immunotherapy, and Phase I clinical trials.